Editas Medicine, Inc.·4

Mar 6, 4:30 PM ET

Mei Baisong 4

4 · Editas Medicine, Inc. · Filed Mar 6, 2023

Insider Transaction Report

Form 4
Period: 2023-03-02
Mei Baisong
SVP, CHIEF MEDICAL OFFICER
Transactions
  • Award

    Common Stock

    2023-03-02+18,00076,372 total
  • Award

    Stock Option (right to buy)

    2023-03-02+54,00054,000 total
    Exercise: $8.72Exp: 2033-03-01Common Stock (54,000 underlying)
Footnotes (2)
  • [F1]The common stock received by the Reporting Person was in connection with the grant of a restricted stock unit award to the Reporting Person, for no consideration, and which is scheduled to vest over four years with 25% of the units vesting on March 2, 2024 and the remaining 75% of the units scheduled to vest in equal quarterly installments thereafter through March 2, 2027.
  • [F2]This option was granted on March 2, 2023 and is scheduled to vest over four years in equal monthly installments beginning on April 2, 2023 through March 2, 2027.

Documents

1 file
  • 4
    form4-03062023_040307.xmlPrimary